Dr Davis on the Investigation of Neratinib + Trastuzumab Deruxtecan in Advanced HER2+ Solid Tumors

Phase I trial of trastuzumab deruxtecan and neratinib in HER2-altered tumorsПодробнее

Final results from the phase 2 SUMMIT basket trial: targeting HER2+ advanced BTCs with neratinibПодробнее

Dr. Hurvitz on the Need for Additional Research With Trastuzumab Deruxtecan in HER2+ Breast CancerПодробнее

The significance of HER2 expression for the activity of trastuzumab deruxtecanПодробнее

Trastuzumab deruxtecan: a promising agent for treating HER2-low breast cancer?Подробнее

Dr. Bunn on Data With Trastuzumab Deruxtecan in HER2-Mutant NSCLCПодробнее

Efficacy of trastuzumab deruxtecan in HER2-low metastatic breast cancerПодробнее

Neoadjuvant therapy with neratinib plus trastuzumab in locally advanced HER2-positive breast cancerПодробнее

TUXEDO-1: trastuzumab deruxtecan for the treatment of HER2-positive breast cancer brain metastasesПодробнее

Study of DS-8201a in HER2-Low, Unresectable and/or Metastatic Breast CancerПодробнее

Clinical Trials Remain Underway for Trastuzumab Deruxtecan in HER2-Positive Breast CancerПодробнее

GS4 10 Neratinib + fulvestrant + trastuzumab for hormone receptor-positive, HER2-mutant metastaticПодробнее

Dr. Anders Discusses the Use of Neratinib/Capecitabine for HER2-Positive Brain MetastasesПодробнее

Phase I/II trial of dendrimer-enhanced SN38 in patients with advanced solid tumorsПодробнее

Neratinib, trastuzumab + fulvestrant for HER2-mutant, HR+, metastatic breast cancerПодробнее

Neratinib in HER2+ Breast CancerПодробнее

Dr. Hamilton Discusses Trastuzumab deruxtecan - NBCLXПодробнее

Trastuzumab deruxtecan in metastatic HER2+ breast cancerПодробнее

Dr. Mohammad Jahanzeb on Neratinib and Trastuzumab in HER2-Positive Breast CancerПодробнее